There is much excitement over the new checkpoint inhibitors, which have shown benefit across a variety of tumors. Right now, researchers are trying to define the subgroup of patients with breast cancer who might be most suited to checkpoint inhibitors, explained Lee Schwartzberg, MD, FACP, chief of Division of Hematology Oncology and professor of medicine at the University of Tennessee Health Science Center.
There is much excitement over the new checkpoint inhibitors, which have shown benefit across a variety of tumors. Right now, researchers are trying to define the subgroup of patients with breast cancer who might be most suited to checkpoint inhibitors, explained Lee Schwartzberg, MD, FACP, chief of Division of Hematology Oncology and professor of medicine at the University of Tennessee Health Science Center.
Transcript (slightly modified)
Are the results of trials evaluating the new checkpoint inhibitors in breast cancer encouraging?
There are trials evaluating the checkpoint inhibitors in breast cancer. We’re very excited about this group of agents, in general, which has shown benefit across a large variety of tumors. The data to date, in breast cancer, has been focused on metastatic disease and there are small populations, typically in phase 1 studies of the checkpoint inhibitors, the PD-1 inhibitors specifically, which have been reported.
The results show that there is some benefit in populations, particularly perhaps in the triple negative breast cancer population. The response rates seem a little bit lower than we see in some other diseases like lung cancer, and certainly lower than we see in a disease that’s very immune sensitive like melanoma. One of the hypotheses is that tumors that have large amount of genomic instability, lots of mutations like lung cancer, are more likely to respond to checkpoint inhibitors.
So part of the drive now in breast cancer is to define the subgroup of patients who might be most suited to checkpoint inhibitors. This is an area of very active discussion and investigation, and I think over the next year or 2 we’ll see much more about checkpoint inhibitors in metastatic breast cancer.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More